iRadimed (NASDAQ:IRMD) Sets New 1-Year High – Here’s What Happened

Shares of iRadimed Corporation (NASDAQ:IRMD) hit a new 52-week high on Monday . The stock traded as high as $97.76 and last traded at $97.3850, with a volume of 9493 shares trading hands. The stock had previously closed at $94.57.

Analysts Set New Price Targets

Several brokerages have commented on IRMD. Zacks Research upgraded shares of iRadimed to a “hold” rating in a research report on Tuesday, November 4th. Roth Capital set a $90.00 price objective on shares of iRadimed in a research note on Friday, October 31st. Weiss Ratings reiterated a “buy (b-)” rating on shares of iRadimed in a report on Thursday. Lake Street Capital reissued a “buy” rating and set a $100.00 target price on shares of iRadimed in a research note on Monday, November 3rd. Finally, Wall Street Zen cut shares of iRadimed from a “strong-buy” rating to a “buy” rating in a report on Sunday, October 26th. Four investment analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $87.33.

iRadimed Stock Up 0.8%

The firm’s 50-day moving average price is $81.57 and its two-hundred day moving average price is $70.16. The firm has a market capitalization of $1.21 billion, a PE ratio of 57.78 and a beta of 1.06.

iRadimed (NASDAQ:IRMD) last posted its quarterly earnings data on Monday, November 3rd. The medical equipment provider reported $0.47 EPS for the quarter, topping analysts’ consensus estimates of $0.43 by $0.04. The firm had revenue of $21.20 million during the quarter, compared to analyst estimates of $20.50 million. iRadimed had a net margin of 26.31% and a return on equity of 22.93%. iRadimed has set its Q4 2025 guidance at 0.470-0.510 EPS and its FY 2025 guidance at 1.840-1.880 EPS. Equities research analysts forecast that iRadimed Corporation will post 1.66 EPS for the current year.

iRadimed Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, November 25th. Investors of record on Friday, November 14th were paid a $0.17 dividend. This represents a $0.68 annualized dividend and a yield of 0.7%. The ex-dividend date of this dividend was Friday, November 14th. iRadimed’s dividend payout ratio is currently 41.21%.

Insider Buying and Selling at iRadimed

In other news, CEO Roger E. Susi sold 5,000 shares of the stock in a transaction that occurred on Monday, November 24th. The shares were sold at an average price of $90.36, for a total value of $451,800.00. Following the completion of the sale, the chief executive officer directly owned 2,307,500 shares of the company’s stock, valued at $208,505,700. This represents a 0.22% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In the last 90 days, insiders sold 50,000 shares of company stock valued at $3,840,650. 36.80% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the stock. PharVision Advisers LLC acquired a new stake in shares of iRadimed during the 3rd quarter valued at $257,000. Virtus Advisers LLC purchased a new stake in shares of iRadimed during the third quarter worth $117,000. Quarry LP purchased a new stake in shares of iRadimed during the third quarter worth $40,000. Qube Research & Technologies Ltd boosted its position in iRadimed by 17.1% during the third quarter. Qube Research & Technologies Ltd now owns 56,826 shares of the medical equipment provider’s stock valued at $4,044,000 after purchasing an additional 8,289 shares during the last quarter. Finally, Punch & Associates Investment Management Inc. acquired a new stake in iRadimed during the third quarter valued at $1,210,000. Institutional investors and hedge funds own 92.34% of the company’s stock.

iRadimed Company Profile

IRadimed Corp. engages in the development, manufacture, marketing, and distribution of Magnetic Resonance Imaging compatible medical devices. It also provides a non-magnetic Intravenous infusion pump system that is specifically designed for use during MRI procedures. The company was founded by Roger Susi in July 1992 and is headquartered in Winter Springs, FL.